Genesys PHO Selects 2bPrecise to Optimize Patient Well-being
Genesys Physicians Hospital Organization (“GPHO”) has selected the 2bPrecise™ precision medicine platform to help improve medication safety and overall patient care. Go-live is scheduled later this month.
The ambulatory physician group in the GPHO network, comprised of 190-plus providers, is implementing the 2bPrecise pharmacogenomics (PGx) solution. Physicians will access information about how patients may or may not respond to specific medications within the native EHR (Allscripts TouchWorks® EHR), through the 2bPrecise Genomic EHR Monitor (GEM™), a flexible, in-workflow applet.
Located in Flint, MI, GPHO serves approximately 250,000 patients in a five-county area. “The value of pharmacogenomics to providers and patients is significant,” says Dr. Gary King, Administrative Medical Director. “Our objective in working with 2bPrecise is to make sure we can make this valuable information useful at the point of care, to support superior clinical decision making and better outcomes for patients.”
2bPrecise, LLC, founded in 2015, was created to “bridge the final mile” between the science of genomics (advancing at dizzying speeds) and the point of care (by making test data and analysis meaningful and actionable for clinicians). An EHR-neutral, cloud-based solution, 2bPrecise consumes data from any lab source and synthesizes it with clinical information to extract meaningful patient-specific insights. The 2bPrecise team’s deep expertise in robust data models and ontologies means 2bPrecise delivers a platform that is extensible and scalable across the healthcare ecosystem, and can be used with new scientific and therapeutic discoveries.
In today’s competitive environment, Dr. King notes, innovations like point-of-care PGx allow providers to actively demonstrate they are future-focused and are adopting new ways to help patients. “The ‘same-old, same-old’ approach to care isn’t good enough,” he said. “Genomics provides us the information that may help in the delivery of more precise care for individuals and to achieve better health management of specific patient populations.”
“Our goal is to help physicians at GPHO achieve therapeutic value faster through the 2bPrecise platform,” says Assaf Halevy, CEO and founder of 2bPrecise, LLC. “Industry leaders like GPHO realize that pharmacogenomics helps deliver a positive return-on-investment over the long term. Once the PGx panel is done, results can be used throughout the patient’s lifetime to impact treatment for a long list of diseases. An enterprise-wide solution like 2bPrecise will help them achieve these benefits.”
2bPrecise, LLC, a wholly owned subsidiary of Allscripts, harnesses the power of genomics and precision medicine in an effort to precisely predict and efficiently treat each individual patient. 2bPrecise’s EHR-agnostic, cloud-based platform captures and stores genomic data and harmonizes it with research knowledge and clinical information. The resulting actionable insights are then pushed into a provider’s existing clinical workflow to facilitate decision-making at the point of care. Learn more at https://2bprecisehealth.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181220005111/en/